Episode 3: How sweet it is to be an SGLT2 Inhibitor

0:00-0:46: Intro
0:47-1:20: Introduction of Dr. Ted Berei
1:21-2:57: DAPA-HF Overview
2:58-6:12: Ted’s Overall Thoughts
6:13-7:24: DAPA-HF Patient Population
7:25-9:15: Sacubitril/valsartan or Dapagliflozin First?
9:16-10:47: Considerations Prior to Starting SGLT2 Inhibitors
10:48-12:19: SGLT2 Inhibitors and Cost
12:20-14:43: Final Thoughts
14:44-15:42: Closing/Introduction to Finn

References: 

• DAPA-HF: McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; DOI: 10.1056/NEJMoa1911303
• CANVAS: Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med2017;377:644-57.
• EMPA-REG: Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28.
• DECLARE-TIMI 58: Wiviott SD, Bonaca MP, Kato ET, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-57.
• 2018 ACC Expert Consensus Decision Pathway for Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol 2018;72(24):3200-23.
• Type 2 Diabetes and Heart Failure: Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. Circulation 2019;140:e294-e324.
• Packer MP, Anker SD, Butler J, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA Cardiol2019;2(9):1025-29.
• Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 2017;19(11):1390-1400.
• Ha CM and Wende AR. The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model. JACC Basic Transl Sci 2019;4(1):38-40.